Drug intelligence / Profile preview

PTG-020

Development stage: Preclinical
Lead developer: PolTREG
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

PTG-020 is a preclinical-stage therapeutic candidate developed by PolTREG SA, primarily focused on treating **Type 1 Diabetes**. It involves the use of **TCR-Tregs (T-cell receptor engineered T-regulatory cells)**, which are a type of cell therapy designed to modulate the immune system and prevent autoimmune attacks. The mechanism involves enhancing the suppressive activity of T-regulatory cells to maintain immune homeostasis and prevent tissue damage.

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on PTG-020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTG-020.

Explore the full profile